A Eissa1, I Krass, B V Bajorek. 1. Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia. ashraf.eissa@sydney.edu.au
Abstract
WHAT IS KNOWN AND OBJECTIVE: Thrombolysis is currently the only evidence-based pharmacological treatment available for acute ischaemic stroke (AIS); however, its current utilization is suboptimal (administered to <3% of AIS patients). The aim of this article was to identify the potential barriers to the use of thrombolysis via a review of the available literature. METHODS: Medline, Embase, International Pharmaceutical Abstracts and Google Scholar were searched to identify relevant original articles, review papers and other literature published in the period 1995-2011. RESULTS AND DISCUSSION: Several barriers to the utilization of thrombolysis in stroke have been identified in the literature and can be broadly classified as 'preadmission' barriers and 'post-admission' barriers. Preadmission barriers include patient and paramedic-related factors leading to late patient presentation for treatment (i.e. outside the therapeutic time window for the administration of thrombolysis). Post-admission barriers include in-hospital factors, such as suboptimal triage of stroke patients and inefficient in-hospital acute stroke care systems, a lack of appropriate infrastructure and expertise to administer thrombolysis, physician uncertainty in prescribing thrombolysis and difficulty in obtaining informed consent for thrombolysis. Suggested strategies to overcome these barriers include public awareness campaigns, prehospital triage by paramedics, hospital bypass protocols and prenotification systems, urgent stroke-unit admission, on-call multidisciplinary acute stroke teams, urgent neuroimaging protocols, telestroke interventions and risk-assessment tools to aid physicians when considering thrombolysis. Additionally, greater pharmacists' engagement is warranted to help identify the people at risk of stroke and support preventative strategies, and provide the public with information regarding the recognition of stroke, as well as facilitate the access and use of thrombolysis. WHAT IS NEW AND CONCLUSION: The most effective interventions appear to be those comprising several strategies and those that target more than one barrier simultaneously. Therefore, optimal utilization of thrombolysis requires a systematic, integrated multidisciplinary approach across the continuum of acute care.
WHAT IS KNOWN AND OBJECTIVE: Thrombolysis is currently the only evidence-based pharmacological treatment available for acute ischaemic stroke (AIS); however, its current utilization is suboptimal (administered to <3% of AIS patients). The aim of this article was to identify the potential barriers to the use of thrombolysis via a review of the available literature. METHODS: Medline, Embase, International Pharmaceutical Abstracts and Google Scholar were searched to identify relevant original articles, review papers and other literature published in the period 1995-2011. RESULTS AND DISCUSSION: Several barriers to the utilization of thrombolysis in stroke have been identified in the literature and can be broadly classified as 'preadmission' barriers and 'post-admission' barriers. Preadmission barriers include patient and paramedic-related factors leading to late patient presentation for treatment (i.e. outside the therapeutic time window for the administration of thrombolysis). Post-admission barriers include in-hospital factors, such as suboptimal triage of strokepatients and inefficient in-hospital acute stroke care systems, a lack of appropriate infrastructure and expertise to administer thrombolysis, physician uncertainty in prescribing thrombolysis and difficulty in obtaining informed consent for thrombolysis. Suggested strategies to overcome these barriers include public awareness campaigns, prehospital triage by paramedics, hospital bypass protocols and prenotification systems, urgent stroke-unit admission, on-call multidisciplinary acute stroke teams, urgent neuroimaging protocols, telestroke interventions and risk-assessment tools to aid physicians when considering thrombolysis. Additionally, greater pharmacists' engagement is warranted to help identify the people at risk of stroke and support preventative strategies, and provide the public with information regarding the recognition of stroke, as well as facilitate the access and use of thrombolysis. WHAT IS NEW AND CONCLUSION: The most effective interventions appear to be those comprising several strategies and those that target more than one barrier simultaneously. Therefore, optimal utilization of thrombolysis requires a systematic, integrated multidisciplinary approach across the continuum of acute care.
Authors: Elisa Giorli; E Schirinzi; R Baldi; A Mannironi; E Raggio; N Reale; C Gandolfo; M Del Sette Journal: Neurol Sci Date: 2019-06-10 Impact factor: 3.307
Authors: Aravind Ganesh; Marie Camden; Patrice Lindsay; Moira K Kapral; Robert Coté; Jiming Fang; Brandon Zagorski; Michael Douglas Hill Journal: CMAJ Open Date: 2014-10-01
Authors: Ilana Spokoyny; Rema Raman; Karin Ernstrom; Bart M Demaerschalk; Patrick D Lyden; Thomas M Hemmen; Amy K Guzik; James Y Chen; Brett C Meyer Journal: J Stroke Cerebrovasc Dis Date: 2013-05-19 Impact factor: 2.136
Authors: Mohit Sharma; Elizabeth Helzner; Richard Sinert; Steven Richard Levine; Ethan Samuel Brandler Journal: Intern Emerg Med Date: 2015-11-09 Impact factor: 3.397
Authors: Darren Flynn; Daniel J Nesbitt; Gary A Ford; Peter McMeekin; Helen Rodgers; Christopher Price; Christian Kray; Richard G Thomson Journal: BMC Med Inform Decis Mak Date: 2015-02-07 Impact factor: 2.796